- Home
- TCRT vs ENSC Comparison
TCRT vs ENSC Comparison
Compare TCRT & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- ENSC
- Stock Information
- Founded
- TCRT 1998
- ENSC 2003
- Country
- TCRT United States
- ENSC United States
- Employees
- TCRT N/A
- ENSC N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- TCRT Health Care
- ENSC Health Care
- Exchange
- TCRT Nasdaq
- ENSC Nasdaq
- Market Cap
- TCRT 3.8M
- ENSC 2.9M
- IPO Year
- TCRT N/A
- ENSC N/A
- Fundamental
- Price
- TCRT $3.01
- ENSC $2.08
- Analyst Decision
- TCRT
- ENSC
- Analyst Count
- TCRT 0
- ENSC 0
- Target Price
- TCRT N/A
- ENSC N/A
- AVG Volume (30 Days)
- TCRT 49.8K
- ENSC 4.9M
- Earning Date
- TCRT 05-19-2025
- ENSC 05-20-2025
- Dividend Yield
- TCRT N/A
- ENSC N/A
- EPS Growth
- TCRT N/A
- ENSC N/A
- EPS
- TCRT N/A
- ENSC N/A
- Revenue
- TCRT $10,000.00
- ENSC $5,210,031.00
- Revenue This Year
- TCRT $5,680,500.00
- ENSC N/A
- Revenue Next Year
- TCRT N/A
- ENSC N/A
- P/E Ratio
- TCRT N/A
- ENSC N/A
- Revenue Growth
- TCRT 100.00
- ENSC 133.58
- 52 Week Low
- TCRT $1.31
- ENSC $1.62
- 52 Week High
- TCRT $14.20
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- TCRT 60.22
- ENSC 39.27
- Support Level
- TCRT $2.56
- ENSC $2.86
- Resistance Level
- TCRT $2.91
- ENSC $3.23
- Average True Range (ATR)
- TCRT 0.28
- ENSC 0.37
- MACD
- TCRT 0.02
- ENSC -0.00
- Stochastic Oscillator
- TCRT 100.00
- ENSC 14.24
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.